Last updated on August 2018

Palbociclib In Progressive Brain Metastases

Brief description of study

This research study is studying palbociclib as a possible treatment for recurrent brain metastases.

  • Pfizer, a pharmaceutical company, is supporting this research study by providing the study drug as well as funding for research activities

Detailed Study Description

  • This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.
    • This is a study designed to evaluate the efficacy and safety of palbociclib in recurrent brain metastases. Palbociclib is being studied for use in the treatment of a broad range of cancers. This type of drug inhibits cell growth in the cells called cyclin-dependent kinases which promote tumor cell proliferation.
    • The FDA (the U.S. Food and Drug Administration) has not approved palbociclib for participants specific disease but it has been approved for other uses

Clinical Study Identifier: NCT02896335

Contact Investigators or Research Sites near you

Start Over

Priscilla Brastianos, MD

Massachusetts General Hospital
Boston, MA United States
  Connect »

Eudocia Lee, MD

Dana Farber Cancer Institute
Boston, MA United States
  Connect »